Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: bobbseytwins2001 who wrote (1049)	5/29/2025 3:43:17 PM
From: luckydog88	1 Recommendation Recommended By erippetoe Read Replies (1) \| Respond to of 1229

I don't have the answer for you, other than I just hope this pops one more time. As of today, May 29, 2025, MarketBeat.com reports that IBRX has a short interest of 73.74 million shares, representing 63.75% of the float. That's pretty high for a $2.50 stock, as you mentioned. A lot of traders are not buying what PSS is selling - hopefully the opportunity for a short squeeze arises.

To: bobbseytwins2001 who wrote (1049)	5/29/2025 4:25:37 PM
From: jargonweary	2 Recommendations Recommended By Fitzhughlaw rodneyh07 Read Replies (1) \| Respond to of 1229

My experience is considerably less than yours but I also don’t understand how shorting this stock at this price makes sense. If the stock was selling around 8-10 I guess I could understand how a short investor might want to gamble on the stock going under 2 on bad news. But the stock continues to trade under 3 and for all of the reasonable doubts and concerns one might have about PSS the company does have an approved drug with decent if not great revenues and the strong possibility of approvals for it in other markets around the world. So the risk/reward of the short position here makes no sense to me, either.

To: bobbseytwins2001 who wrote (1049)	5/29/2025 5:48:27 PM
From: Redman1234	1 Recommendation Recommended By bobbseytwins2001 Respond to of 1229

Hedge Funds are likely basing their decision to short with the expectation of catalysts to disappoint based on past history. Manufacturing issues, RTF, and current cash burn rate. I’m still looking for UK NICE and European approval this year, but a lot rest on whether NSCLC BLA filing for AA this year or early next? NSCLC Is the money maker that proves Anktiva treats multiple cancers. With half the upper management having left or given the pink slip in FDA unfortunately there are bound to be delays which will only help Hedge Funds shorting. Taken everything into consideration I’m still buying at $3 or below with expectation of delays and news pushed back until 2026. I hope am wrong, but I am patient because I believe in Anktiva.

To: bobbseytwins2001 who wrote (1049)	5/29/2025 6:17:21 PM
From: Maturin	3 Recommendations Recommended By End2War jargonweary waitwatchwander Read Replies (2) \| Respond to of 1229

Early in my career I worked for a publicly traded energy company that had run into financial challenges, and it was there that I began to learn about the complex trades put on by sophisticated institutional investors. Our company was severely leveraged and it seemed only a matter of time before an eventual bankruptcy filing, but nevertheless the executive team was able to refinance the debt a few times and buy 4-5 more years of life as a public company. All the while the company stock was heavily shorted. At the time I thought the shorts were simply speculators who guessed that oil and gas prices would not recover enough to stave of a restructuring. I later learned that many of the short sellers were holders of our subordinated debt. Seems that if you are a debt holder and concerned that there wont be enough left to pay you out during a bankruptcy, you can short the company equity as a hedge against your debt position. Could this be happening at IBRX? Perhaps, though I don't know enough about who owns the debt.

To: bobbseytwins2001 who wrote (1049)	5/30/2025 11:30:45 AM
From: End2War	2 Recommendations Recommended By sukit waitwatchwander Read Replies (1) \| Respond to of 1229

I fed your posted question to Chat GPT, and here is what it said: Here’s a comprehensive reply to that IBRX post that unpacks the strategic and technical possibilities behind the surge in short interest despite the stock’s low price: You're asking a very good question — and you're not the dumbest kids on the block for raising it. In fact, the mechanics of this kind of short interest buildup, particularly in a sub-$3 biotech stock like IBRX (ImmunityBio), can be counterintuitive unless you account for certain structural dynamics. Here's a breakdown of the most plausible explanations for the recent ~6 million share increase in short interest: 1. Convertible Arbitrage IBRX has outstanding convertible debt, notably its ~$500 million note due in 2026 with a conversion price of $5.32 per share. This sets up a classic convertible arbitrage trade: Institutions buy the convertible bonds to collect interest (in this case 3.75%). Simultaneously, they short the common stock to hedge the delta exposure on the conversion option. Even at low prices, this trade continues as long as the bond still has conversion value or optionality (including default/credit risk hedging). If a fund expects dilution or price weakness, they may increase their short position even further, especially near key catalyst dates like FDA decisions or financing events. 2. Hedging Against a PIPE or Structured Equity Facility IBRX has previously raised capital through structured financing involving equity-linked facilities. If such a facility was renewed or expanded in Q2 2025 (not yet publicly disclosed but possibly hinted at in the 10-Q or investor chatter), it could incentivize preemptive short selling by the counterparties involved. In that case: The investor gets shares at a discount in the future. They short now against those expected shares to lock in profits regardless of direction. These short sales inflate short interest but are not directional bets — they’re part of a cash-and-carry arbitrage. 3. Anticipation of J-Code and "Buy the Rumor, Sell the News" IBRX is preparing for Anktiva’s permanent J-code to take effect in Q1 2025, with growing sentiment that Q4 sales will be modest until billing clarity arrives. That sets up a news-based short thesis: Short interest rises as traders anticipate weak Q4 results or a delay in billing ramp-up. If actual revenue disappoints, or Medicare claims lag, a quick drop below $2 could be profitable even from a $2.50 entry. Small moves in penny stocks = large percentage gains. 4. Low Borrow Cost and Options Market Support IBRX shares are still relatively easy to borrow, and liquid weekly options allow shorts to: Hedge or lever short positions cheaply. Use put spreads or collars to manage risk around biotech binary events (e.g., label updates, FDA approvals). Even a 20–30 cent drop on a $2.50 base is a 10–12% gain, which is highly attractive on a hedged basis with tight options. 5. Tax and Balance Sheet Trades Some institutions may short against the box for tax or balance sheet reasons: Fund A wants to delay realizing gains or losses but reduces exposure by shorting. A market-neutral fund wants flat exposure but liquidity in the bond vs. equity legs differs, so they rebalance by shorting. These aren’t directional bets — they’re strategic. Final Thoughts: You're not missing anything obvious — it is a strange setup if viewed through a traditional retail or long-only institutional lens. But in biotech, especially with convertible debt and financing overhangs, short interest can rise dramatically for non-directional and arbitrage-related reasons. If you're long and fundamentally bullish on Anktiva sales, FDA label expansion, and J-code ramp-up in 2H 2025, then the rising short interest could eventually become fuel for a squeeze — particularly if there’s unexpected good news. But until then, these trades are often just mechanics of risk management by the more sophisticated arms of the street.